In the latest session, Atea Pharmaceuticals Inc (NASDAQ: AVIR) closed at $3.99 down -1.24% from its previous closing price of $4.04. In other words, the price has decreased by -$0.0500 from its previous closing price. On the day, 518530 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Atea Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.24 and its Current Ratio is at 18.24. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On January 06, 2022, Morgan Stanley Downgraded its rating to Underweight which previously was Equal-Weight and also lowered its target price recommendation from $14 to $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 01 when Sommadossi Jean-Pierre sold 56,910 shares for $3.85 per share. The transaction valued at 218,819 led to the insider holds 116,557 shares of the business.
Horga Maria Arantxa sold 15,870 shares of AVIR for $60,963 on Feb 01. The Chief Medical Officer now owns 25,664 shares after completing the transaction at $3.84 per share. On Feb 01, another insider, Corcoran Andrea, who serves as the insider of the company, sold 15,843 shares for $3.84 each. As a result, the insider received 60,915 and left with 670,208 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVIR now has a Market Capitalization of 335.82M and an Enterprise Value of -239.89M. Its current Enterprise Value per Revenue stands at 58.97 whereas that against EBITDA is 1.46.
Stock Price History:
Over the past 52 weeks, AVIR has reached a high of $5.19, while it has fallen to a 52-week low of $2.77. The 50-Day Moving Average of the stock is 3.7776, while the 200-Day Moving Average is calculated to be 3.5058.
Shares Statistics:
For the past three months, AVIR has traded an average of 490.04K shares per day and 419.72k over the past ten days. A total of 83.44M shares are outstanding, with a floating share count of 73.79M. Insiders hold about 12.33% of the company’s shares, while institutions hold 64.13% stake in the company. Shares short for AVIR as of Feb 15, 2024 were 1.62M with a Short Ratio of 3.31, compared to 3.73M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.94% and a Short% of Float of 2.53%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.61 for the current quarter, with a high estimate of -$0.57 and a low estimate of -$0.63, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.68, with high estimates of -$0.62 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$2.5 and -$3.03 for the fiscal current year, implying an average EPS of -$2.76. EPS for the following year is -$2.92, with 3 analysts recommending between -$2.5 and -$3.14.
